FRM
IRWD icon

Fox Run Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Fox Run Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,141
Closed -$138K – 950
2024
Q2 		$138K Buy
+21,141
New +$150K 0.03% 706
2023
Q2 		– Sell
-19,668
Closed -$207K – 819
2023
Q1 		$207K Buy
+19,668
New +$220K 0.07% 523
2021
Q3 		– Sell
-15,214
Closed -$196K – 548
2021
Q2 		$196K Buy
+15,214
New +$174K 0.18% 292
2018
Q2 		– Sell
-15,007
Closed -$194K – 791
2018
Q1 		$194K Buy
+15,007
New +$187K 0.05% 639
2017
Q2 		– Sell
-27,223
Closed -$389K – 716
2017
Q1 		$389K Sell
27,223
-8,955
-25% -$122K 0.16% 267
2016
Q4 		$463K Buy
+36,178
New +$457K 0.24% 146

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's IRWD Position: Q3 2024 in Review

Fox Run Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2024, closing a stake of 21,141 shares — an estimated $138K sold.

Fox Run Management first reported a position in IRWD in Q4 2016 and held it in 6 quarters. The position peaked at $463K in Q4 2016. 221 funds tracked by Wall St. Rank hold IRWD as of Q3 2024.

  • Fox Run Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 21,141 Ironwood Pharmaceuticals shares in Q3 2024, an estimated $138K.
  • Fox Run Management first reported a position in Ironwood Pharmaceuticals in Q4 2016 and held it in 6 quarters.
  • Fox Run Management's Ironwood Pharmaceuticals position peaked at $463K in Q4 2016.
  • 221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.